Tempest Therapeutics (NASDAQ:TPST) reported an insider purchase on March 24, 2026, with Chief Executive Officer and president Angel Matthew buying 231,482 shares of the company's common stock at $2.16 per share. The total value of the transaction was $500,001. The acquisition was made indirectly through Factor Bioscience Inc., an entity where Mr. Matthew holds the roles of chief executive officer and chairman of the board.
The purchase came while the stock was trading near its 52-week low of $1.65 and following a sharp week-over-week decline. Tempest shares had fallen 19% over the prior week and were trading at $1.74 at the time of the report. Independent valuation analysis from InvestingPro included in the disclosure indicates a Fair Value of $2.34 for the stock.
Following the transaction, Mr. Matthew's direct ownership in Tempest stands at 4,837,070 shares. The filing notes the acquisition route through Factor Bioscience rather than a direct open-market purchase.
Financing and corporate developments
Tempest also announced the completion of a private placement that generated approximately $2 million in gross proceeds. The financing involved the sale of 925,927 shares of common stock or pre-funded warrants, and included series A warrants along with short-term series B warrants.
As part of its strategic repositioning, Tempest finalized the acquisition of dual-targeting CAR-T programs from Factor Bioscience and its affiliates. This transaction expanded the companys pipeline with next-generation CAR-T assets and accompanied the firms stated pivot into CAR-T therapy.
Clinical data disclosed
Tempest reported clinical results from its REDEEM-1 Phase 1/2a trial. The update stated that all six efficacy evaluable patients achieved a complete response in the treatment of relapsed/refractory multiple myeloma. The company presented these findings alongside its other corporate and financing news.
Analyst action and shareholder implications
Following the strategic moves into CAR-T and the related acquisitions, H.C. Wainwright upgraded Tempests rating from Neutral to Buy and set a price target of $11.00. The analyst cited the companys pivot into CAR-T therapy and the acquisition of four dual-targeting CAR-T programs as context for the upgrade. The transaction structure leaves existing shareholders with approximately 35% ownership on a pro forma basis, with full warrant coverage noted in the analyst commentary.
In addition to public filings, the disclosure referenced that InvestingPro provides 15 additional exclusive tips for TPST intended to shed further light on the companys financial position and market stance.
Context and immediate market signals
The insider purchase and corporate updates arrive while the stock trades near its annual low and after a recent steep weekly decline. The company has combined new financing, an expanded CAR-T portfolio through acquisition, and favorable early clinical data into its latest public disclosures, while at least one sell-side analyst has moved to a Buy rating with an $11.00 price target.
Observers will note the mix of insider buying, fresh capital, early-stage clinical outcomes from a small evaluable cohort, and analyst optimism as the principal elements shaping the recent narrative around Tempest.